BIA China Special Interest Group Webinar Update on China biopharma landscape and partnering





BIA welcome





Steve Bates CEO BioIndustry Association

China Special Interest Group



The China SIG was set up with the China-Britain Business Council (CBBC), and supported by the Department for International Trade (DIT).

- To home in on issues with Britain/China collaboration and investment *specific to biotechnology and early stage companies*
- To provide a network of support and information for companies exploring the possibilities and provide a forum for candid input from group members
- To act as a forum for UK companies to actively engage with UK-China biotech activities and the UK government's business development strategies in the sector. To include details of high-level official visits; conferences & trade shows; missions; seminars; meetings and any other relevant events in the sector
- O Ultimately to provide a Forum for UK organisations in the sector to explore the opportunities for them to grow their business in and with China, via trade & investment









- Regulation of drugs has changed with a new approach from the Chinese regulator The National Medical Products Administration (NMPA)
- **Re-imbursement** procedures have changed for this huge market
- Talent policies to get experienced leaders to return "sea turtles" are working and an ecosystem is developing
- **Capital** and Public Markets
- o Improved Access to markets



September 2019 - BIA announced major initiative with AstraZeneca and new state of the art lifescience innovation campus in Wuxi China





November 2019 Shanghai, China

BIA supported a UK Investor Track at the China Healthcare Summit. Six member companies came out to present



Organized by BioCentury and BayHelix in collaboration with McKinsey & Co.









WuXi Healthcare Forum in Shanghai, March 2019





Boao Forum in Hainan Province, March 2019





Xiamen delegation, September 2019



Guangxi delegation, December 2019



WuXi Global Forum, January 2020



Covid disruption – maintaining relationships and continued collaboration





Key Learnings from Coronavirus Challenge and Innovating for a Sustainable Future

Zoom Webinar


2nd April, 2020 10:00 - 11:30 (UTC+00:00) / 17:00 - 18:30 (UTC+08:00)



I.Campus



The 3rd China-UK Economic and Trade Forum & The Launch Ceremony of '2020 Report on the Development of Chinese Enterprises in the UK'



第三届中英经贸论坛 暨《2020 英国中资企业发展报告》发布会

Covid disruption –

maintaining relationships and continued collaboration







Contact Info UK BioIndustry Association: Miriam Gedge mgedge@ Biolinoustry Association, ministrational score madge@wuxiapptec.com ix Apptec Group: Dave Madge dave madge@wuxiapptec.com Denastment of International trade: Qionger He gionger.he@fco.gov.uk Tel 008613818204106

Update on Opportunities in China: policy and regulatory changes



Josh Berlin Executive Director of BD BioCentury



Hamish King COO Cisema



Katherine Wang Ropes & Gray



Qun Yang COO & Co-Founder **Biorbyt** Ltd.

BIOCENTURY

www.bioindustry.org

BA

National Security & Investment Regime





- Regime came into force on **4 January 2022**
- Applies to transactions on or after 12 November 2020

Sector definition: Synthetic Biology



Exceptions - human or veterinary medicines or immunomodulatory approaches

6.—(1) Exceptions to the activities described in paragraph 2 are the ownership, ownership of intellectual property or development of the matters set out in sub-paragraph (2) that employ synthetic biology at any stage of the development or production, unless the circumstances set out in sub-paragraph (3) apply.

- (2) The matters referred to in sub-paragraph (1) are-
 - (a) human or veterinary medicines;
 - (b) immunomodulatory approaches.

(3) The circumstances referred to in sub-paragraph (1) are where the matter described in sub-paragraph (2)—

- (a) has a synthetic biology technology that could be employed or modified to produce, deliver or produce and deliver—
 - (i) toxic chemicals to achieve an incapacitating or lethal effect on humans or animals;
 - (ii) materials restricted under Schedule 5 to the Anti-terrorism, Crime and Security Act 2001(a); or
- (b) uses substances or pathogens set out in Schedule 5 to the Anti-terrorism, Crime and Security Act 2001.

More information



• ISU can be contacted for informal discussions and to answer any

questions: investment.screening@beis.gov.uk



Going forwards -



"It does not matter how slowly you go so long as you do not stop." Confucius

- Strong and stable, an enduring endeavour
- Shared Global Agendas AMR
- Pandemic Preparedness
- Regulation of new technologies

Contact



The BioIndustry Association, 7th Floor, Southside, 105 Victoria Street, London, SW1E 6QT • Tel: +44 (0)20 7630 2180

BIA China Special Interest Group Webinar Thursday 26 May

Tom Duke Deputy Trade Commissioner, China Department of International Trade



Policy reform to meet healthcare needs

- China now one of the fastest countries to launch new medicines
- Faster, better drug approval: 61 in 2021
- Drugs developed overseas account for 49% of 2021 approvals





Building up biotech

- Chinese government pledged to increase R&D spending by 7% a year to 2025
- Seven target areas including: brain science, clinical sciences & healthcare, and genetics & biotechnology



• China's 2020 spend on R&D is at 2.4% of GDP




Funding is available

- Venture capital
- Pharmaceutical companies looking for strategic investments
- High quality assets, facilities, and expertise


Venture Dollar Volume By Country In Asia, Through Q4 2021

Includes seed, venture and private equity to venture-backed companies



Track record of global partnerships

- Chinese companies are going global, inlicensing and out-licensing assets at all phases
- 171 China-inward cross-border licensing deals in 2021
- Top 5 country originators:
 - USA
 - South Korea
 - Japan
 - UK
 - Canada




Department for International Trade (DIT)

- Individual, bespoke support including:
 - Licensing and investment
 - Intellectual property, patents
 - Policy, regulatory, business support, exports
- Partnering British and Chinese companies
- Sponsor and host events





ChinaBio – September 2022, Beijing




Interested in joining our virtual delegation? Contact <u>ruijia.zhang@fcdo.gov.uk</u>







UK-China Business Connect







Our team in China



Gary Hunt – Shanghai Assistant Director Life Sciences & Healthcare gary.hunt@fcdo.gov.uk



Win-Yan Chan – Beijing Head of Pharma winyan.chan@fcdo.gov.uk



Ruijia Zhang – Chongqing Senior Trade and Investment Officer ruijia.zhang@fcdo.gov.uk



Ning Ma – Beijing Senior Trade and Investment Officer ning.ma@fcdo.gov.uk



Fang Ma – Beijing (Mat Leave) Senior Trade and Investment Officer <u>ma.fang@fcdo.gov.uk</u>





BIA: Update on China biopharma landscapeand partnering opportunities26 May 2022

The background

Overview of Diurnal:

- UK-based, European specialty pharmaceutical company
- Focused on rare and niche endocrine diseases
- Pipeline concentrated on repurposing of existing (off-patent) compounds

ased to first national los of rare decases https://doc.org/df.ase

we the parts for space, the Ostanov Goromant is an pair space structure to your diverses and it is the part of the parts of the parts

Backdrop to China opportunity:

- Convergence of several factors
 - Increased focus on treatment of paediatric disease
 - First National List of Rare Diseases published (May 2018)
 - Lists 121 diseases, CAH amongst them
 - Initiatives around treatment of rare diseases
 - e.g. establishment of Rare Disease Treatment Centre, Hainan

Environment conducive to establishment of new companies focused on rare diseases





Change in rare disease backdrop lead to Diurnal being approached by around 20 companies, through:

- Partnering meetings e.g. BioEurope
- Website directly
- Introductions by DIT

• Experiences of process:

- Validation of companies can be challenging (no Companies House)
 - DIT extremely helpful in validation
- Complexity of corporate structures
 - Approached by two companies separately in same group DIT assisted here
- Local visit highlighted sophistication of distribution networks
- Understanding local regulatory requirements (and changes)
- Board concerns e.g. intellectual property, successor products
- Chinese law vs. English law
 - Access to lawyer with local expertise





The process

The deals



Two deals executed with RareStone (Citrine):

- Alkindi (hydrocortisone modified-release hard capsules) (Jan 2021)
 - Exclusive license for China, Hong Kong, Taiwan and Macau
 - Rarestone responsible for further development, regulatory, commercial
 - \$0.5 million upfront
 - Up to \$12.75m milestones
 - Royalties on sales
- **Efmody** (hydrocortisone granules in capsules for opening) (May 2021)
 - Scope as per Alkindi
 - \$1.0 million upfront
 - Up to \$28.75m milestones
 - Royalties on sales



	Diumal	
27 January 2021	Diurnat	
	Diumal Group plc ("Diumal" or the "Company")	
China lio	encing agreement with Citrine Medicine for Alkindi [®]	
Diumal parts	ners with China-based rare disease therapeutics company	
Total up-front payment an	d future milestones of up to \$13.25 million, with double-digit royalties on	
	asies	
andorring (hormonal) disease	(), the specialty pharmaceutical company targeting patient needs in chronic set, announces that it has entered into an exclamar isomore agreement for fororthonic granules in capacity, with the speciality littine Medicine, Inc. ("Citrine") covering China, Hong Kong, Tawan and	
Under the terms of the licer \$0.5 million and will receiv regulatory milestones and sa royables on sales ranging fro	nce agreement, Durmal will receive a non-refundable upfront payment of e \$12.75m in additional cash payments upon adrievement of certain use mitestones based on annual sales thresholds. Diurnal will receive tiered om low to mid double-digita.	
by Vivo Capital, F-Ptime Cap	form company focused on the Greater China market that was co-founded plai and Eight Roads Ventures. Citrine is focused on creating a therapeutic	
platform to deliver ran ecosystem in the court		
Citrine will be respons		
China and for all com utilize product from Dir		Diurnal
China in the future. It i in China ¹ , CAH is a gr	12 May 2021	Diarriac
was identified a rare d	iz may ave i	
Martin Whitaker, CE	Diumal Group pic ("Diumal" or the "Company")	
With the increased fo we are delighted to he		P10100000
by Citrine's vision for equilatory and comme	China licensing agreement with Citrine Medicine for	1999 - Shama
are well positioned to a a major breakthrough	Partnership extended with China-based rare disease therap	eutics company
with CAH, where then	Total up-front payment and future mileotones of up to \$29.75 million, w sales	ith double-digit royalties on
Melissa Bradford-Kit		
unmet need. We are y	Diumal Group pic (AIM: DNL), the specialty pharmaceutical company larg	eting patient needs in chronic
new medicine to pa collaborations to bene	endocrine (hormonal) diseases, announces it has extended its exclusiv specially pharmaceutical company. Citrine Medicine, Inc. ("Citrine").	e licence agreement with the to include the registration.
with biopharma comp China."	specially pharmaceutical company, Chrine Medicine, Inc. (Citrine'), distribution and marketing of Ethnody [®] (hydrocortisone modified-release) name Chronocort [®]) covering China, Hong Kong, Talwan and Macau.	hard capsules - development
This announcement (Under the terms of the licence agreement, Diumal will receive a non-re \$1.0 million and will receive \$25.75 million in additional cash payments	ifundable upfront payment of
596/2014 (MAR).	\$1.0 million and will receive \$28,75 million in additional cash payments regulatory milestones and sales millestones based on annual sales threat tiered royalities on sales ranging from low to mild double-digits.	upon achievement of certain tolds. Diurnal will also receive
Zhong, K. et al. (201		
Screening, 23(2), pp.1	Citrine is a therapeutics platform company focused on the Creater China by Vivo Capital, F-Prime Capital and Eight Roads Ventume, Tothme is too, platform to deliver rare disease drugs to the Chinese market and to drev ecosystem in the country. The Company signed an original licensing agr 2021 for obtaining registration for Alkind [®] (hydrocottone granules in ca for all commercialisation activities in China.	used on creating a therapeutic.
	Chrise will be responsible for collationy registration for Elbody ¹ as track conditions competital advertised in URAH and advertal insufficie commercialisation activities, including prioring and reinstrumenter. Chrise Duran's European scipty of units, with an opdomic to establish in toom suge the science of the science of the science of the science of the Duran's European scipty of the science of the science of the Duran's European scipty of the science of the science of the Duran's European scipty of the science of the science of the Duran's European science of the science of the science of the Duran's European science of the science of the science of the Duran's European science of the Science of the Science of the science of the Rest Science of the Science of the science of the science of the science of the authorities in May 2016.	will initially utilise product from ly chain in China in the future. oup of genetic conditions that
	Munitiv Whitelawy, CE Do 10 Distrato, consententiet. Was les planses has scalar due understrativa and Cabine in Chrise to ine referency products. We have been impressed by Cahne's local commercialisation experises the Askans ⁴ and robust bor takes to the applied to Ethnong ⁴ . Pollowing the recent possible CHMP option necel- leticating applientia is non-activate and those antiloging optimies mixed access planses and the application of the antiloging optimies mixed access treatment and the application of the antiloging optimies mixed access treatment for Christer patient and the antiloging optimies mixed access theorem and the application of the application of the physiological where there is a significant uniter planet need.	levelopment, regulatory and ledge and experience being d for Etmody [®] in Europe, this of our products outside of key in China as the first licensed.
	Melinsa Bradford-Klug, President and Chief Business Officer of Citr 'Ti a with much exclament that we extend our identity agreement with mobile us to serve the needs of Chinese advantion of all ages suffering th are great partners and we look forward to continuing to work with them- Bitmody [®] through the resolution approved process in China.	Diurnal, which will ultimately on CAH. The team at Diurnal

Innovent

Innovent Biologics


BIA CHINA SPECIAL INTEREST GROUP MEETING

Astrid <u>Maria</u> Dahl Chief Operating Officer and Head, Innovent Biologics (Europe) MAY 26th 2022



To develop and commercialize high quality biopharmaceuticals that are affordable to ordinary people.

Innovent's First 10 Years Growth: A Solid Track Record



Transformed from a biotech start-up to a leading biopharma company in China

Innovent

Confidential Copyright©2022 Innovent

Innovent Biologics 2022 – A Global Player



Building Leading Commercial Franchise with Expanding Approved and Late-stage Portfolio in Near Term

Robust I	ate Stage As	sets for Grow	vth						
Robust Late Stage Assets for Growth					TA	Target/Asset	Product	Status	Indication
	Oncology/ Non-Oncology				PD-1 (sintilimab)	TYVYT [®]	Launched	cHL	
Broad Patients and Big Market ☆☆☆☆☆ ☆				Δ		CD20 (rituximab)	HALPRYZA®	Launched	NHL
	ΤΥΥΥΤ®	IBI-362	ZAN Shittmaphifection	600	Hematology	BCR/ABL (olverembatinib)	NAILIKE	Launched	CML
	CYRAMZA®	PCSK9	ATTA ALL ALL COM			BCMA CART (Equecabtagene Autoleuce)	IBI-326	NDA in 1H2022	MM
			这位同 "			PI3K (parsaclisib)	IBI-376	Pivotal Ph2	FL
	BYVASDA®	VEGF/C	VEGF/C		Lung Cancer	PD-1 (sintilimab)	TYVYT®	Launched	1L sqNSCLC; 1L nsqNSCLC
	CTLA-4					PD-1 (sintilimab)	TYVYT [®]	Launch in 2022	EGFR+ NSCLC
						RET (selpercatinib)	RETSEVMO®	Launch in 2022	RET+ NSCLC
				$\cup $		ROS1 (taletrectinib)	IBI-344	Pivotal Ph2	ROS1+ NSCLC
	HALPRYZA®	SULINNO®	4			KRAS G12C	IBI-351	Ph1	KRAS+ NSCLC
Clear Unmet Need and Good Opportunity ☆☆☆☆☆				evmo"	Liver Cancer	PD-1 (sintilimab)	TYVYT ®	Launched	1L HCC
	Pemazyre®	IL-23	Determo			VEGF-A (bevacizumab)	BYVASDA®	Launched	1L HCC
	Olverembatinib	PDE4	Retevmo			VEGFR2 (ramucirumab)	CYRAMZA®	Launched	2L GC
	RETESVMO [®]	A. M	達伯坦》			CTLA-4 (ipilimumab)	IBI-310	Ph3	1L HCC
		🔆 这伯华"		S	Gastrointestinal	FGFR1/2/3 (pemigatinib)	PEMAZYRE®	Launched	CCA
	BCMA CAR-T	1-22-1- 利用者会议证书	- many - function			PD-1 (sintilimab)	TYVYT [®]	Launch in 2022	1L GC
	ROS1/NTRK					PD-1 (sintilimab)	TYVYT [®]	Launch in 2022	1L ESCC
	ΡΙ3Κδ*					VEGFR2 (ramucirumab)	CYRAMZA [®]	Launched	2L GC
					KRAS G12C	IBI-351	Ph1	CRC, PC, etc.	
						CLDN18.2	IBI-360;IBI-345;IBI-389	Ph1	GC, PC, etc.
Franchise and Synergy in TAs				S	Gynecological	PD-1 (sintilimab)	TYVYT ®	Pivotal Ph2	2L CC
			CTLA-4 (ipilimumab)			IBI-310	Pivotal Ph2	2L CC	
						VEGF-A (bevacizumab)	BYVASDA®	Launched	OC, CC
				Metabolic	PCSK-9 (tafolecimab)	IBI-306	NDA in 1H2022	nFH, HeFH	
					GLP1/GCGR	IBI-362	Ph3 in 2022	Diabetics, Obesity	
The second se				2 23	Autoimmune	TNF α (adalimumab)	SULINNO [®]	Launched	RA, AS, Psoriasis, PJIA, Uveitis
			IL-23			IBI-112	Ph3 in 2022	Psoriasis; Ulcerative colitis	
Oncology Metabolic Autoimmune Ophthalmology				0		PDE4 (orismilast)	IBI-353	Ph3 in 2023	Psoriasis; Atopic Dermatitis
						VEGF/C (efdamrofusp alfa)	IBI-302	Ph2	nAMD
Innovent					Confidential Copyright©2022 Innovent				4

Internally Focus on 7 Major Research Taskforces to Deliver Global Potential Drugs

With the goal to discover, develop and commercialize potential global blockbuster drugs by 2030, we have 80 research programs at pre-clinical stage supported by state-of-the-art protein and antibody engineering technologies.



Confidential Copyright©2022 Innovent

BD Strategy is Complementary to Innovent's Globalization Strategy



As our BD transactions align with our strategy – we lay a strong path for globalization.

Innovent

Confidential Copyright©2022 Innovent

Overview of HitGen Advancing Innovative Drug Discovery

HitGen Inc. (688222.SH)

May, 2022



Disclaimer

This presentation has been prepared by HitGen Inc.(the "Company"). The information contained in this presentation is intended for information purpose only and does not take your investment objectives, financial status, and special needs into consideration. This presentation does not constitute legal, regulatory, accounting tax or investment advice to you, or any form of financial opinion or recommendation by the Company or any other party at any time. We recommend that you seek independent third party legal, regulatory, accounting, tax, investment advice regarding the contents of this presentation.

The Company is not making any offer of its securities and cannot accept orders for any securities at this time. This presentation does not constitute an offer to sell or issue or a solicitation of any offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into investment activity, nor may it or any part of it form the basis of or be relied upon in connection with any contract or commitment whatsoever. Specifically, this presentation does not constitute a "prospectus" within the meaning of the Securities Act.

This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. All relevant information relating to the Company should be subject to the information disclosed publicly by the Company. In this presentation, may be cited statistics from the history of public release of the data or information. The information herein is preliminary and subject to change and its accuracy is not guaranteed. The information included herein was obtained from various sources, including certain third parties, and has not been independently verified.

NO REPRESENTATION, WARRANTY OR UNDERTAKING, EXPRESS OR IMPLIED, IS MADE AS TO, AND NO RELIANCE SHOULD BE PLACED ON, THE FAIRNESS, ACCURACY, COMPLETENESS, TIMELINESS, APPROPRIATENESS OR CORRECTNESS OF THE INFORMATION CONTAINED HEREIN. NONE OF THE COMPANY OR ANY OF ITS AFFILIATES, SHAREHOLDERS, DIRECTORS, EMPLOYEES, AGENTS, ADVISORS OR REPRESENTATIVES WILL BE LIABLE FOR ANY LOSS HOWSOEVER ARISING FROM ANY USE OF THIS PRESENTATION OR ITS CONTENTS OR OTHERWISE ARISING IN CONNECTION WITH THIS PRESENTATION OR ITS CONTENTS (INCLUDING BUT NOT LIMITED TO NEGLIGENT REPRESENTATION OR OMISSION).

Unless otherwise instructed by the company in writing, the company is the sole and exclusive owner of all right, title, and interest in and to all the information under this presentation.



About HitGen





- HitGen was founded in 2012, headquartered in Chengdu, China
- Subsidiaries outside China include Vernalis (R&D) Ltd in Cambridge, UK and HitGen Pharmaceuticals Inc. in USA
- HitGen has ~500 employees (20%PhD, 30%MS), >20,000 m² laboratory and office space
- HitGen focuses on DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies, synthetic therapeutic oligonucleotide(STO) and targeted protein degradation (TPD) offering a full set of research capabilities from target to IND filing and project pipeline in oncology, immunology and inflammation
- HitGen is listed on Shanghai Stock Exchange (688222.SH)




Vernalis (R&D) Limited



◆ Founded in 1996; Cambridge, UK-based

- Full suite of capabilities and facilities for drug discovery
- One of the world leaders in fragment and structurebased drug discovery
 - Innovation in adopting and adapting methods, particularly in biophysics
- A team of ~70, most with over 20 years of drug discovery experience



- Drug discovery collaborations from target to candidate
 - 6 development candidates in the past 5 years
 - ◆ 20 families of Joint Patents granted
 - Disclosed partners include: Asahi Kasei Pharma, Lundbeck, Servier, PhoreMost
 - Multi-target collaborations in Target Enablement
 - Focus on challenging, novel, previously undrugged targets; disclosed with Servier and Genentech



Corporate Strategy Upgrade


ONE Vision: To build a world-class Innovative biopharmaceutical enterprise and contribute to better life and health of mankind

Two Types of Innovative Drugs: Small molecules; Nucleic acid drugs

Three Business Models: Technical services; Project out-licensing; Product sales


Four Core Technology Platforms: To develop a leading technology matrix with key capabilities for drug discovery and optimization to support continuous innovative drug research, development, and production.

- DNA-encoded library (DEL)
- Fragment-based drug discovery and structurebased drug design (FBDD/SBDD)
- Synthetic therapeutic oligonucleotide (STO)
- Targeted protein degradation (TPD)






HitGen Innovative Drug Discovery Research Platform



DEL: DNA-Encoded Library FBDD/SBDD: Fragment-Based Drug Discovery and Structure-Based Drug Design STO: Synthetic Therapeutic Oligonucleotide TPD: Targeted Protein Degradation



Business development underpinned by strong R&D investment



Expanding Drug Discovery Pipeline (2021)

Around **20** in-house drug discovery projects at different stages. Four programmes received NMPA's approvals of IND and are in Phase I clinical study.



New-generation inhibitor for Trk/ROS1. HitGen's first project receiving IND approvals by both NMPA and FDA to conduct clinical trials.



A selective small molecule inhibitor for Class I/IIb HDAC. Multiple Myeloma (MM).

HG146

A selective small molecule inhibitor of Class I/IIb HDAC. Solid tumor.






HG030

Target:	NTRK/ROS1 Inhibitor
Indication:	Solid Tumor
Clinical Trial Stage:	Phase I
IND application approved from FDA in Jan. 2022	



HG146

Target:	I/lia HDAC Inhibitor
Indication:	Multiple Myeloma & Solid Tumor
Clinical Trial Stage:	Phase I



HG381

Target:	STING Agonist
Indication:	Solid Tumor
Clinical Trial Stage:	Phase I



HitGen Business Models



DELs: DNA Encoded libraries; FBDD/SBDD: Fragment-Based Drug Discovery/Structure-Based Drug Design STO: synthetic therapeutic oligonucleotide; TPD: Targeted Protein Degradation

HitGen Collaboration Partners (in public)



Welcome to Visit us









Welcome to visit us by www.hitgen.com or www.vernalis.com or scan 2D barcode.

欢迎访问我们的网站: www.hitgen.com or www.vernalis.com 或扫描左侧的二维码





A National credit endorsement business partner for Chinese market

Since 1984 Meheco is here in China for you!



2022



Industry Position

Administration Commission of the State Council (SASAC)

Backbone state-owned enterprise directly administered by the central government

China General Technology (Group) Holding Co., Ltd.

Genertec's main plaform of medicine & medical devices business

China Meheco Group Co., Ltd. (Stock Code: 600056)

China Meheco - Main International Platform (import and export)

> China Meheco Corporation

- •Three main activities: advanced manufacturing & technical service, medicine & medical health, international trade & engineering service
- •Rank No. 430 in the Fortune Global 500

•One of the three centrally-administered state-owned enterprises in medicine & medical industry in China

•Over 330 medical institutions, over 46,000 beds, over 26 million outpatient service times per year

One of the three centrally-administered state-owned enterprises in medicine and medical industry in China in the A shares market
Ranked 3rd in the Top 100 Chinese Medicine and Health Products Import and Export Enterprises

Window of "Bring in" and " Go global" strategy of China Meheco
Undertakes the mission of National Pharmaceutical Stockpile and special medicine import business. Chinese outstanding enterprise in the fight against the COVID-19 epidemic.

• Ranked 2nd in the Top 100 Chinese Medicine Import Enterprises





Genertec's Medical Institution Landscape in China

Genertec has established a national landscape of medical institutions in China, and has become a centrallyadministered state-owned medical group leading in bed number, Internet facility and industry chain building.

Till May 2022,





330 medical institutions in 26provinces in China (include 27 Grade3 hospitals, 69 Grade 2 hospitals)

over 46,000 beds



over **26 million** times of outpatient services per year







Import Business

Import scope

- Finish dosage
- Biological products
- Diagnostic products
- Medical equipments
- Medical consumables
- Health products
- Herbal products
- 2nd psychoactive drug

Business model

General distribution

Domestic distribution

Terminal direct sales

Import business

Import service..

Service

- Product registration
- Import
- Warehousing
- Logistics
- Bonded and other fully managed customized operation models

Marketing Network

- Hospitals
- Research institutes
- Inspection and quarantine institutions
- Provincial and municipal blood stations
- Research institutes
- Domestic pharmaceutical and medical product distributors and pharmaceutical production enterprises, etc.



Import Businesses

Warehousing and Logistics

We have modern logistics centers in multiple locations and can provide our customers with integrated supply chain and logistics services. Totally have 41 warehouses located in different main cities in China, cold storage warehouse also available.

Beijing Logistics Center



Import Businesses

On Line Platforms & Cross Boarder Business

On Line Cross Boarder Flagship Shop

On Line Flagship Store






Brands we are working with: medisum Nature Made Triomar goodhealth Triomar Swisse Size Seven elevit



Production Bases in China



令 中国医药 Integrated Service of Pharmaceutical Commercial Supply Chain in China

China Meheco is a leading medicine, medical device, health product distributor in China. We have vast terminal coverage, and a medicine commercial system with industry value chain integration synergy effect.

Medical institution partners: 20,000+

Direct sales to Grade 3 A hostitals: 1000+

Retail pharmacy partners: 16,000+



Capabilities of Meheco that can Help You Win

- ✓ Central enterprise platform and powerful financing ability
- ✓ Full-fledged business networks and powerful terminal coverage
- ✓ Integrated service platform and quality brand influence
- ✓ Efficient talent team and comprehensive service provider
- ✓ Quality control system and registration support
- ✓ Production facilities and capacity of nearly all kinds of formulation
- ✓ Modern Logistic system and integrated comprehensive services

Product registration

Import,Warehousing, logistics, and bonded services Sales & marketing in China (Production if needed)



Contact

Julie Liu / BD Deputy GM Tel: 0086 10-67108821 Mob: 0086 13681372732 (Whatsapp & Wechat & BOTIM) Email: liuxiaoyu@mehecointl.com.cn Skype: julieliu712